Belkin Unveils New IPod Touch Cases To Raise Money For Cancer Research

Posted: Sep 30 2009, 8:00am CDT | by , Updated: Aug 11 2010, 4:32pm CDT, in News | Apple

 
/* Story Top Left 2010 300x250, created 7/15/10 */ google_ad_slot = "8340327155";

Buy This Now On Amazon

Belkin has announced a couple of new cases for the iPod touch that will help raise money for breast cancer research by donating a portion of the proceeds to research. The two cases are the DualFit for the Cure and the Grip for the Cure.

The DualFit case fits arms any size and has a clear screen protector. Other features of the case include a key pocket and the case is covered in a reflective material for nighttime use. The other case is called the Grip for the Cure.

The case is form fitting for less bulk and has a textured exterior for better grip. Both of the cases will sell for $29.99 and will ship in mid-October. Belkin will donate $2.50 from each case sold with a minimum donation of $100,000 going to the Susan G. Komen for the Cure foundation.

Holiday Gift Guides and Deals

Get your Holiday gifting inspired by Best Toy Gifts with High STEM Value and the Top 10 toy gifts under $10 if you are on budget. The most popular Holiday 2017 toy list include Fingerlings, Crate Creatures and more. Don't miss the new Holiday deals on Amazon Devices, including $29.99 Fire tablet.

This story may contain affiliate links.

This free App Solves You Holiday Shopping Problem


Download the free Tracker app now to get in-stock alerts on Fingerling, Luvabella, SNES Classic and more.

Latest News

Comments

The Author

<a href="/latest_stories/all/all/3" rel="author">Shane McGlaun</a>
Tech and Car expert Shane McGlaun (Google) reports about what's new in these two sectors. His extensive experience in testing cars, computer hardware and consumer electronics enable him to effectively qualify new products and trends. If you want us review your product, please contact Shane.
Shane can be contacted directly at shane@i4u.com.

 

 

Advertisement

comments powered by Disqus